Therefore 100% are positive. Zogenix had 9 analyst reports since August 6, 2015 according to SRatingsIntel. Brean …
Stock market analysts and brokers have recently amended their target prices on shares of Zogenix, Inc. (ZGNX). According to the latest research reports released, 3 analysts have issued a rating of “buy”, 1 analysts “outperform”, 1 …
SmarTrend identified an Uptrend for Zogenix Inc (NASDAQ:ZGNX) on February 9th, 2017 at $9.50. In approximately 5 months, Zogenix Inc has returned 50.00% as of today's recent price of $14.25. In the past 52 weeks, Zogenix Inc …
Zogenix, Inc. Receives Buy Rating from Stifel Nicolaus - Stock Observer Zogenix, Inc. Runs 2.74 percent For the Week - Concord Register This media report from www.streetinsider.com distributed on June 26, 2017 was a factor to the next …
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in …
(Original Source) Shares of Zogenix closed last Friday at $15.22, up $0.24 or 1.60%. ZGNX has a 1-year high of …
That is because ZGNX recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. What is a Hammer Chart Pattern? A hammer chart pattern is a popular technical indicator that is used in candlestick charting. …
Zogenix Inc. (NASDAQ: ZGNX) has been a controversial small cap drug stock, with its abuse-deterrent Zohydro being at front and center. Now that the company has submitted its supplemental new drug application (sNDA) with the U.S. …
SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX [FREE Stock Trend Analysis]), a pharmaceutical company developing and commercializing products for the treatment of central nervous system …
In addition to the $35 million acquisition cost in cash and Zogenix stock (11,995,202 shares to be registered), the terms of the purchase agreement includes $50 million in potential regulatory milestone payments and up to $45 million in royalty …